Compounded Tirzepatide: Why It Exists, Why Regulators Warn and What ‘Compounded’ Really Means

The ad arrives between a weather update and a cousin’s vacation photos: a smiling woman, a small glass vial, and the word ‘personalized’ in a soft serif font. Scroll a little further and there is another, this time promising tirzepatide in a tablet. Neither mentions that the window that allowed pharmacies to mass-produce copies of this medicine closed in early 2025.

That gap between the marketing and the rulebook is why searches for compounded tirzepatide keep climbing. As of mid-2025, the US Food and Drug Administration (FDA) has formally declared the shortage of the approved injectable over, the grace periods for compounders have expired, and yet telehealth storefronts continue to advertise ‘compounded’ pens, vials, drops and tablets.

This piece is not about whether weight-loss medicines work. The best of them clearly do, in large randomized trials. It is about a narrower and more useful question: what exactly is in a compounded product, why it ever existed, and what the evidence can and cannot tell you about it.

What does 'compounded' actually mean in compounded tirzepatide?

Compounding is the practice of a licensed pharmacist or physician combining, mixing or altering ingredients to create a medicine tailored to one patient. In plain terms, it is a drug made for you rather than made for everyone. The classic examples are humble: a liquid version of a tablet for a child who cannot swallow pills, or a cream without a dye that triggers a patient’s allergy.

Two features define a compounded product, and both matter for tirzepatide. First, it is not FDA-approved. The approval process that an original medicine goes through, with manufacturing inspections, stability testing and the clinical trials that prove benefit and catalogue harms, does not apply to the compounded copy. The pharmacy is regulated, but the specific product on the shelf has never been evaluated by the agency.

Second, compounding is legally restricted to situations where a commercially available medicine will not do. US law allows pharmacies to make what is ‘essentially a copy’ of an approved drug only when that drug is in shortage or when a patient has a documented clinical need the branded version cannot meet. Making copies simply because they are convenient, or because demand is high, falls outside those rules.

Compounded tirzepatide, then, is tirzepatide active ingredient obtained from a bulk supplier, dissolved and packaged by a compounding pharmacy or outsourcing facility, and sold under a prescription. It contains, in theory, the same molecule as the approved injection. Whether it contains the same amount, in the same purity, at the same stability, with the same sterility, is exactly what nobody outside that pharmacy has independently verified. That is not an insult to pharmacists. It is a description of what approval does and does not cover.

Why did compounded tirzepatide exist in the first place?

Scarcity created it. Tirzepatide was approved for type 2 diabetes in 2022 and for chronic weight management in late 2023, and demand outran manufacturing almost immediately. In December 2022 the FDA added the injectable to its official drug shortage list. That listing is the legal trigger that permits pharmacies to compound copies of a commercially available drug.

Two kinds of facility stepped in. Traditional ‘503A’ pharmacies, which compound for individual patients on a prescription-by-prescription basis, and ‘503B’ outsourcing facilities, which operate under stricter federal manufacturing standards and can produce larger batches. Both sourced the raw peptide from bulk chemical suppliers, then prepared it as a liquid for injection.

Why did patients and prescribers reach for it? Three reasons recur in clinical conversations. Supply: patients already established on the approved product were suddenly unable to fill their prescriptions and faced interruptions that could undo months of progress. Access: insurance coverage for obesity treatment remains patchy, and a prescription for the branded product does not always translate into a filled one. And convenience: a telehealth visit, a mailed vial and a monthly video check-in felt, to many, like the healthcare they had always wanted.

Those motivations are human and understandable, and the shortage was real. The problem is what happened next. An exception designed for a temporary gap became, for roughly two years, an entire parallel market. By the time supply recovered, hundreds of thousands of people were using a product that had never been through a clinical trial, prescribed by clinicians who often had never examined them in person. The legal basis for that market was always the shortage. When the shortage ended, so did the basis.

What changed recently

The timeline matters because the marketing often ignores it.

• October 2, 2024: The FDA announced that the shortage of tirzepatide injection had been resolved, based on manufacturer data showing supply met or exceeded national demand.
• December 19, 2024: After a legal challenge from a compounding trade group and a re-evaluation of supply, the agency reaffirmed its decision. Tirzepatide was no longer in shortage.
• February 18, 2025: The grace period ended for 503A pharmacies. Compounding tirzepatide that is essentially a copy of the approved product became subject to enforcement.
• March 19, 2025: The equivalent grace period ended for 503B outsourcing facilities.

Since then, two things have happened. Regulators have continued to publish warnings about adverse event reports linked to compounded versions, particularly dosing errors with multi-dose vials. And a portion of the market has reinvented itself. Some sellers now advertise ‘personalized’ tirzepatide, with added vitamins or unusual strengths, arguing that the product is no longer a copy of the approved drug. Others have shifted to oral tablets or sublingual drops, formulations that have never been approved for this peptide in any form.

None of this changes the underlying clinical evidence, which comes from the approved product. The pivotal weight-management trial, published in the New England Journal of Medicine in 2022 and indexed on PubMed, tested manufacturer-produced injectable tirzepatide against placebo for 72 weeks. Every number you have seen about 15 to 20 percent weight reduction comes from that supply chain, not from a compounding pharmacy. As of mid-2025, no randomized trial of compounded tirzepatide, injectable or oral, has been published.

Why regulators warn about compounded tirzepatide

Regulatory warnings about compounded tirzepatide rest on four concerns, each documented rather than hypothetical.

Dosing errors. The approved product arrives in a prefilled pen that delivers a fixed amount. Compounded versions typically arrive as a vial and separate syringes. Patients are expected to draw up a volume themselves, often converting between units written on the label and the markings on the syringe. The FDA has described receiving reports of people administering several times their intended amount because of confusion between milliliters, units and milligrams. Severe nausea, vomiting and dehydration followed, with some requiring hospital care.

Unverified ingredients. Some compounders have used salt forms of the molecule, such as tirzepatide sodium or acetate. A salt form is the active compound bound to another ion to make it easier to handle. The FDA has stated these are not the same active ingredient as in the approved product and do not meet the legal conditions for compounding. Independent testing by regulators has also found some bulk peptides with impurities or different potency from what the label claimed.

Sterility. Anything injected under the skin must be sterile. The 2012 fungal meningitis outbreak traced to a compounding pharmacy, which killed more than 60 people, is the reason outsourcing facilities now exist under federal oversight. Smaller pharmacies operate under state rules that vary widely.

Unproven formats. Tablets, drops and nasal sprays containing tirzepatide have no approval, no published absorption data and no efficacy evidence. A peptide swallowed is largely digested like any other protein.

Notice what is absent from this list: a claim that the molecule itself is dangerous. The concern is the uncontrolled chain between a bulk supplier and your skin.

How tirzepatide works, in plain language

Tirzepatide mimics two gut hormones at once. After a meal, the intestine releases glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), signaling molecules that tell the pancreas to release insulin, slow the emptying of the stomach and inform the brain that enough has been eaten. Tirzepatide is a laboratory-built peptide that activates the receptors for both, and it is modified to last roughly a week in the bloodstream rather than minutes.

The practical effects line up with that mechanism. Blood sugar after meals falls, because insulin rises in step with glucose. Appetite drops, and many patients describe a quieter kind of hunger, with less of the background ‘food noise’ that makes dieting exhausting. Food sits in the stomach longer, which contributes to fullness and, unhelpfully, to nausea and constipation.

Why does this matter for a conversation about compounding? Because the molecule’s effectiveness depends on precise properties: the exact amino acid sequence, the fatty-acid chain attached to it that lets it bind to albumin in the blood and resist breakdown, and a stable solution that keeps the peptide folded correctly until it is injected. Peptides are fragile. Heat, light, agitation and the wrong pH can cause them to clump or degrade. The approved product’s stability has been tested across its labeled shelf life and storage conditions. A compounded vial has, at best, a ‘beyond-use date’ assigned by the pharmacy, and the data behind it is rarely published.

A medicine that works by mimicking hormones with exquisite precision is, in other words, exactly the kind of medicine where manufacturing shortcuts are hardest to see and easiest to feel.

What the evidence actually says, and how strong it is

Evidence comes in grades, and honesty means naming them.

Strong evidence (randomized controlled trials) for approved tirzepatide. The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight plus a weight-related condition, without diabetes, and randomized them to tirzepatide or placebo for 72 weeks alongside lifestyle counseling. Average weight reduction ranged from about 15 to 21 percent across the three studied doses, against roughly 3 percent with placebo. The SURPASS program, in people with type 2 diabetes, showed larger reductions in HbA1c, a three-month average of blood sugar, than several comparator medicines. Later trials have reported benefits for obstructive sleep apnea and heart failure with preserved ejection fraction. This is high-quality evidence, with the usual caveats that trials select motivated participants and that weight tends to return after stopping.

Moderate evidence (observational data) on adverse effects. Large insurance-database studies have examined rates of pancreatitis, gallbladder disease and gastroparesis in GLP-1 receptor agonist users. They suggest modestly increased risks of gallbladder problems and, less consistently, pancreatitis. Observational studies cannot fully separate the medicine from the people who take it.

Weak or absent evidence for compounded tirzepatide. There are no randomized trials. There are no published pharmacokinetic studies, which would measure how much drug reaches the blood, for any compounded injectable, tablet or drop. What exists is a growing body of adverse event reports and regulator laboratory analyses. Reports cannot establish how common a problem is, only that it has happened.

So the honest summary is lopsided. The molecule is among the best-studied weight-management medicines ever developed. The compounded copy is among the least studied products many people have ever injected.

Is compounded tirzepatide safe? What clinicians look for

Safe compared with what? That question, which sounds evasive, is the only way to answer honestly.

Compared with the approved product, compounded tirzepatide carries every risk of the molecule itself plus a layer of manufacturing uncertainty that cannot be quantified from the outside. Compared with unsupervised use of a ‘research peptide’ bought online, a compounded product from a state-licensed pharmacy with a real prescriber is a meaningfully more controlled situation. Both comparisons are true, and neither makes the compounded version equivalent to the approved one.

When physicians who specialize in obesity medicine talk about what they check, a few themes recur. They want to know whether the pharmacy is a 503B outsourcing facility that follows federal current good manufacturing practice, or a 503A pharmacy under state oversight. They ask for a certificate of analysis for the specific batch, a document showing a laboratory tested that lot for identity, potency and endotoxins, the bacterial fragments that cause fever. They look at the label: is the active ingredient listed as tirzepatide, or as a salt form? Are strengths expressed clearly in both concentration and volume? Does the product arrive cold, with instructions that match the syringes supplied?

They also check the prescribing side. A medicine that slows the stomach, lowers blood sugar and triggers nausea needs a baseline: current medications, especially insulin or sulfonylureas, kidney function, history of pancreatitis or gallstones, pregnancy plans, and a family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, which are listed contraindications.

Research peptides sold ‘not for human use’ sit outside all of this. They are not medicines, not sterile by any verified standard, and not for self-use under any circumstance.

Compounded tirzepatide vs brand name: a side-by-side comparison

A table is the quickest way to see where the two products genuinely differ and where they do not.

Feature	FDA-approved tirzepatide	Compounded tirzepatide
Regulatory status	Approved after review of trials and manufacturing	Not approved; legal only under narrow compounding exceptions
Clinical trial evidence	Multiple randomized trials, tens of thousands of participants	None published
Active ingredient	Tirzepatide, manufacturer-synthesized and verified	Bulk peptide of variable source; salt forms reported
Delivery device	Prefilled single-dose pen or vial with matched instructions	Usually multi-dose vial with separate syringes
Dosing error risk	Low; fixed delivery	Higher; patient-measured volumes, unit conversions
Sterility assurance	Inspected manufacturing, tested every lot	Varies by facility type and state oversight
Stability data	Tested across labeled shelf life and storage	Pharmacy-assigned beyond-use date, rarely published
Adverse event tracking	Mandatory manufacturer reporting	Voluntary reporting; limited traceability
Oral formulations	None approved	Marketed without absorption or efficacy data

The row people most often miss is ‘adverse event tracking’. When something goes wrong with an approved product, a lot number connects the event to a specific production run and the manufacturer is legally required to report it. With many compounded products, the trail ends at the pharmacy, which makes it harder for anyone, including regulators, to spot a bad batch early. That difference does not show up on the label and it does not show up in a glossy ad. It shows up only when something has already gone wrong.

Compounded tirzepatide tablets, drops and 'oral' versions: what the science allows

If injectable compounding is a regulatory gray area, oral tirzepatide is something else entirely. It is a product for which there is no approved reference, no absorption study and no plausible mechanism for working as advertised.

The reason is biochemistry rather than regulation. Tirzepatide is a peptide, a chain of 39 amino acids. The stomach and small intestine exist precisely to break such chains into fragments. The one GLP-1 receptor agonist that has been approved as a tablet, oral semaglutide, required a dedicated absorption enhancer and years of formulation work, and even then only a small fraction of the swallowed dose reaches the bloodstream. No equivalent technology has been developed, tested or approved for tirzepatide.

Sublingual drops, held under the tongue, are marketed on the premise that the peptide absorbs through the mouth’s lining. That lining is a reasonable route for some small molecules. For a large peptide carrying a fatty-acid chain, there is no published human data showing meaningful absorption. Nasal sprays face the same problem.

What does the evidence say about these products? Nothing, because none has been studied. Regulators have warned that they are unapproved and have flagged that some labels list the active ingredient as a salt form. Patients who report appetite suppression with a tablet may be experiencing a placebo effect, which in weight-loss studies is genuinely large, or the effect of other ingredients in the product. Neither is the same as the trial-proven effect of injected tirzepatide.

The clinical consequence is quiet but real: a person who believes they are on tirzepatide, and who is not, may delay a treatment that actually works. These products are not approved, not evidence-based and not appropriate for self-use.

Tirzepatide side effects: what the 'bad side' looks like

People searching for the bad side of tirzepatide are asking a fair question, and the trials answer it in detail. The following applies to the molecule itself; compounded products add the manufacturing risks discussed above on top.

Gastrointestinal effects dominate. In SURMOUNT-1, nausea affected roughly a quarter to a third of participants on tirzepatide, with diarrhea, constipation and vomiting each in the range of 10 to 25 percent depending on dose. Most episodes were mild to moderate and clustered around dose increases, then faded. About 4 to 7 percent of participants stopped the medicine because of side effects, compared with around 3 percent on placebo.

Less common but more serious effects include gallbladder disease, which rises with rapid weight loss from any cause; acute pancreatitis, reported in trials and in observational data at low rates; and low blood sugar, which is uncommon with tirzepatide alone but becomes a real risk when it is combined with insulin or sulfonylureas. Severe vomiting can lead to dehydration and acute kidney injury. There are case reports of delayed stomach emptying causing problems with anesthesia, and anesthesiologists now routinely ask about these medicines before procedures.

Thyroid C-cell tumors occurred in rodents given GLP-1 receptor agonists, which is why the label carries a boxed warning and the medicine is not used in people with a personal or family history of medullary thyroid carcinoma. Whether this translates to humans remains unproven.

Finally, loss of lean mass accompanies weight loss with any method, and several studies suggest a quarter or more of the weight lost may be muscle unless resistance exercise and adequate protein are part of the plan. That is not a reason to avoid the medicine. It is a reason to treat it as one tool, not the whole toolbox.

Common myths about compounded tirzepatide, corrected

‘It is the same drug, just cheaper.’ The intent is the same molecule. Whether a given vial contains that molecule at the stated strength and purity, with no contaminants, has not been independently verified in the way approval requires. Same intent is not same product.

‘Personalized tirzepatide with added vitamins is a different medicine, so compounding it is fine.’ Adding an ingredient does not automatically create a clinical need that the approved drug cannot meet. Regulators have specifically questioned formulations that appear designed to sidestep the ‘essentially a copy’ rule rather than to address a documented patient requirement.

‘Compounded pharmacies are inspected, so the product is as safe as a manufacturer’s.’ Pharmacies are licensed and inspected, but inspection of a facility is not the same as review of a product. Approval tests the specific formulation for stability, sterility and potency across its life. Licensing confirms the pharmacy meets practice standards.

‘Oral tirzepatide works just as well as the shot.’ No oral tirzepatide has been approved anywhere, and no absorption or efficacy data has been published. Peptides are digested when swallowed.

‘The shortage is still on, so compounding is still legal.’ The FDA declared the shortage resolved in October 2024 and reaffirmed it in December 2024. Grace periods for compounders ended in February and March 2025.

‘Side effects mean it is working.’ Nausea reflects slowed stomach emptying, not fat loss. In trials, people who tolerated the medicine well lost comparable amounts of weight to those who felt unwell.

‘If I react badly, at least I know it was the medicine.’ With a compounded product, you may not know whether the reaction came from the peptide, an impurity, a dosing error or a contaminated vial. That uncertainty is itself a harm.

Can you still get compounded tirzepatide?

The legal answer and the practical answer have drifted apart, which is why this question keeps appearing in search.

Legally, the broad permission to compound copies of tirzepatide ended with the shortage. Since February and March 2025, pharmacies and outsourcing facilities that continue to produce what regulators consider essentially a copy of the approved product do so against the agency’s stated enforcement position. Narrow exceptions remain in principle: a patient with a documented, specific clinical need that the approved product cannot satisfy, such as a verified allergy to an inactive ingredient. Those cases are individual and rare, and they require the prescriber to document the need.

Practically, products are still marketed. Some telehealth companies have shifted to ‘personalized’ strengths or added ingredients. Others continue to ship products under legal arguments that have not yet been tested in court. Regulators have sent warning letters, and enforcement priorities can change, but the marketplace has not disappeared overnight.

What this means for a reader is not a shopping question but a medical one. The people best placed to interpret your situation are your own clinicians: whether you have a documented need that the approved product cannot meet, whether a transition to the approved product is appropriate, and how to do that safely if so. This article will not tell you where to find any product, and no responsible source should. It can tell you that the evidence supporting tirzepatide comes entirely from the approved version, and that the regulatory basis for widespread compounding no longer exists.

If you are currently using a compounded product, the single most useful step is to tell your prescriber exactly what you are taking, including the pharmacy name and the label details, so that any decision is made with full information.

What matters most: the questions worth asking your prescriber

After two years of watching this market, one opinion seems well supported by the evidence: the question ‘compounded or brand’ is less important than the question ‘who is looking after me while I take this?’

Tirzepatide is a powerful medicine with a predictable side-effect profile and a handful of serious risks. Managed well, with a stepwise increase in dose, attention to hydration, protein and strength training, and a clinician who knows your full medication list, it produces results few other treatments can match. Managed poorly, it produces dehydration, muscle loss, missed red flags and, when the prescription ends, rapid weight regain. The product’s origin changes the manufacturing risk. The quality of care changes almost everything else.

Questions worth bringing to an appointment, whatever product is under discussion:

• What is my individual goal, and how will we measure it beyond the scale: blood pressure, blood sugar, sleep, joint pain, waist measurement?
• Which of my current medicines interact with slowed stomach emptying or lower blood sugar?
• What is the plan for protecting muscle during weight loss?
• How will dose increases be decided, and what symptoms should prompt a pause?
• What happens if I need surgery or become pregnant while on this medicine?
• What is the long-term plan, including whether and how we would ever stop?

A prescriber who can answer those without hesitation is offering something no vial can. A seller who answers every question with a link to check out is offering something else. The decision about whether tirzepatide is right for you, in any form, rests with that prescriber, and the evidence they will be relying on, if they are honest, comes from the approved product.

When to see a doctor

Anyone taking tirzepatide, approved or compounded, should know the signs that need prompt medical attention. Seek urgent care, by emergency services if symptoms are severe, for any of the following:

• Severe, persistent abdominal pain, especially pain that spreads to the back, with or without vomiting. This can signal pancreatitis.
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can indicate gallbladder disease.
• Vomiting that prevents you from keeping fluids down for more than a day, dizziness on standing, very dark urine or passing little urine. Dehydration can injure the kidneys.
• Symptoms of low blood sugar: shakiness, sweating, confusion, racing heart, particularly if you also take insulin or a sulfonylurea.
• A lump or swelling in the neck, hoarseness, or trouble swallowing, which should be assessed given the thyroid warning on the label.
• Signs of an allergic reaction: swelling of the face or throat, difficulty breathing, widespread rash.
• Redness, warmth, pus or spreading pain at an injection site, which may indicate infection and is a particular concern with multi-dose vials.
• Sudden changes in vision if you have diabetes.

Contact your prescriber, non-urgently but soon, if you suspect you may have injected more than intended, if a vial looks cloudy or discolored or contains particles, if nausea or constipation is affecting your ability to eat and drink normally, if you are planning surgery or a procedure requiring sedation, or if you are pregnant, breastfeeding or planning pregnancy.

Never stop, restart, switch or change the amount of a prescribed medicine on your own. If you are using a compounded product, bring the vial and its label to your appointment. Every decision about starting, continuing or changing tirzepatide belongs with the clinician who knows your history and can examine you.

Frequently asked questions

Can you still get compounded tirzepatide?

The broad legal permission to compound copies of tirzepatide ended after the FDA declared the shortage resolved, with grace periods expiring in February and March 2025. Some sellers continue to market products under altered formulations, and regulators have issued warnings in response. Narrow exceptions exist only for documented individual clinical needs the approved product cannot meet. Whether any of this applies to you is a question for your prescribing clinician, not for an advertisement.

Is compounded tirzepatide better than regular tirzepatide?

No evidence suggests compounded tirzepatide is better, and no randomized trial has tested it at all. The approved product is supported by trials in tens of thousands of participants, with verified manufacturing, stability testing and a fixed-dose pen that limits measuring errors. A compounded version can at best match the molecule; it cannot exceed it, and it adds uncertainty about potency, purity and sterility that the approved product does not carry.

Is the lowest starting dose of tirzepatide enough to lose weight?

The starting dose of tirzepatide is designed to let the body adjust and reduce nausea, not to deliver the full effect. In trials, weight loss began during the early weeks but the largest reductions occurred at higher maintenance doses reached through stepwise increases. Some people respond well at lower doses, and tolerance varies. How quickly, how far and whether to increase is an individual decision for your prescriber based on your response and side effects.

What is the bad side of tirzepatide?

The most common downsides are gastrointestinal: nausea, vomiting, diarrhea and constipation, usually around dose increases and usually temporary. Less common but serious risks include pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar when combined with insulin or sulfonylureas, and muscle loss alongside fat loss. The label carries a thyroid tumor warning based on rodent studies. Compounded versions add manufacturing and dosing risks on top of these.

Is compounded tirzepatide safe to inject if it comes from a licensed pharmacy?

A license confirms the pharmacy meets practice standards; it does not confirm the specific product has been tested for potency, purity, sterility and stability the way an approved medicine is. Outsourcing facilities operating under federal manufacturing rules offer more assurance than smaller pharmacies under variable state oversight, but neither equals approval. Regulators have documented dosing errors, salt-form ingredients and impurities in compounded products. Safety is relative, and the person to assess it is your clinician.

What is the difference between compounded tirzepatide vs brand name products in the vial?

In principle, both contain the same 39-amino-acid peptide. In practice, the approved product is synthesized, purified and tested by the manufacturer under inspected conditions, then supplied in a fixed-dose pen or matched vial. A compounded product uses bulk peptide of varying origin, sometimes a salt form regulators say is not equivalent, prepared by a pharmacy with its own beyond-use date. The molecule may be the same; the verification behind it is not.

Do compounded tirzepatide tablets or drops actually work?

There is no evidence that they do. Tirzepatide is a peptide that the digestive system breaks down like any other protein, and no absorption-enhancing technology has been developed, tested or approved for it in oral or sublingual form. No human absorption or efficacy data has been published for these products. Any appetite change experienced with them cannot be attributed to tirzepatide reaching the bloodstream. They are unapproved and not appropriate for self-use.

Why do regulators warn about dosing errors with compounded tirzepatide?

Because the delivery format invites them. The approved pen delivers a fixed amount with one click. Compounded vials require the patient to draw up a volume with a syringe, often converting between units, milliliters and milligrams written differently on the label, the prescription and the syringe. Regulators have described reports of people administering several times their intended amount, leading to severe nausea, vomiting, dehydration and hospital visits.

What are the most important tirzepatide side effects to tell a doctor about?

Severe or persistent abdominal pain, especially radiating to the back; pain in the upper right abdomen with fever or yellowing skin; vomiting that prevents keeping fluids down; symptoms of low blood sugar such as shakiness, sweating or confusion; a neck lump or hoarseness; signs of allergy; and infection at an injection site. Milder nausea or constipation that interferes with eating also deserves a conversation, since dose adjustments are decided by your prescriber.

If I am already using a compounded product, what should I do?

Tell your prescribing clinician exactly what you are using, including the pharmacy, the labeled ingredient and strength, and how you measure each injection, ideally bringing the vial to the appointment. Do not stop, change or switch on your own. Your clinician can review whether the approved product is appropriate for you, how any transition would be handled, and whether your current product raises specific concerns given your health history and other medicines.

References

• MedlinePlus: Tirzepatide Injection
• Cleveland Clinic: GLP-1 Agonists
• NHS: Obesity, Treatment

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.